Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1981 1
1982 2
1986 2
1988 1
1989 2
1990 1
1991 2
1992 2
1993 3
1994 3
1995 2
1996 3
1997 1
1998 3
1999 2
2000 1
2001 3
2002 4
2003 6
2004 2
2005 4
2006 13
2007 12
2008 3
2009 7
2010 11
2011 11
2012 14
2013 16
2014 16
2015 12
2016 16
2017 14
2018 22
2019 13
2020 9
2021 6
2022 5
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

226 results

Results by year

Filters applied: . Clear all
Page 1
Intravitreal aflibercept for diabetic macular edema.
Korobelnik JF, Do DV, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metzig C, Brown DM. Korobelnik JF, et al. Among authors: vitti r. Ophthalmology. 2014 Nov;121(11):2247-54. doi: 10.1016/j.ophtha.2014.05.006. Epub 2014 Jul 8. Ophthalmology. 2014. PMID: 25012934 Clinical Trial.

The corresponding proportions of eyes gaining 15 letters were 41.6% and 31.1% versus 7.8% (P < 0.0001) in VISTA, and 32.4% and 33.3% versus 9.1% (P < 0.0001) in VIVID. Similarly, mean reductions in central retinal thickness were 185.9 and 183.1 versus 73.3 mum

The corresponding proportions of eyes gaining 15 letters were 41.6% and 31.1% versus 7.8% (P < 0.0001) in VISTA, and 32.4% and 33.

Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies.
Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metzig C, Holz FG. Heier JS, et al. Among authors: vitti r. Ophthalmology. 2016 Nov;123(11):2376-2385. doi: 10.1016/j.ophtha.2016.07.032. Epub 2016 Sep 17. Ophthalmology. 2016. PMID: 27651226 Clinical Trial.

RESULTS: Mean BCVA gain from baseline to week 148 with IAI 2q4, IAI 2q8, and laser control was 10.4, 10.5, and 1.4 letters (P < 0.0001) in VISTA and 10.3, 11.7, and 1.6 letters (P < 0.0001) in VIVID, respectively. The proportion of eyes that gained 15 letters

RESULTS: Mean BCVA gain from baseline to week 148 with IAI 2q4, IAI 2q8, and laser control was 10.4, 10.5, and 1.4 letters (P < 0.

Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
Brown DM, Wykoff CC, Boyer D, Heier JS, Clark WL, Emanuelli A, Higgins PM, Singer M, Weinreich DM, Yancopoulos GD, Berliner AJ, Chu K, Reed K, Cheng Y, Vitti R. Brown DM, et al. Among authors: vitti r. JAMA Ophthalmol. 2021 Sep 1;139(9):946-955. doi: 10.1001/jamaophthalmol.2021.2809. JAMA Ophthalmol. 2021. PMID: 34351414 Free PMC article. Clinical Trial.

At 24 weeks, treatment with aflibercept resulted in a 2-step or greater improvement in DRSS level in 157 of 269 eyes (58.4%) in the combined aflibercept groups vs 8 of 133 eyes (6.0%) in the control group (adjusted difference, 52.3%; 95% CI, 45.2%-59.5%; P < .001). At 5

At 24 weeks, treatment with aflibercept resulted in a 2-step or greater improvement in DRSS level in 157 of 269 eyes (58.4%) in the combined …
INTRAVITREAL NESVACUMAB (ANTIANGIOPOIETIN 2) PLUS AFLIBERCEPT IN DIABETIC MACULAR EDEMA: Phase 2 RUBY Randomized Trial.
Brown DM, Boyer DS, Csaky K, Vitti R, Perlee L, Chu KW, Asmus F, Leal S, Zeitz O, Cheng Y, Schmelter T, Heier JS; RUBY Investigators. Brown DM, et al. Among authors: vitti r. Retina. 2022 Jun 1;42(6):1111-1120. doi: 10.1097/IAE.0000000000003441. Epub 2022 Feb 22. Retina. 2022. PMID: 35234673 Free PMC article. Clinical Trial.

Central subfield retinal thickness reductions at Week 12 were -169.4, -184.0, and -174.6 m (nominal P = 0.0183, HD combo vs. IAI); Week 36 reductions for LD combo and HD combo q8w and q12w versus IAI were -210.4, -223.4, and -193.7 versus -61.9 m (nominal P < 0.0

Central subfield retinal thickness reductions at Week 12 were -169.4, -184.0, and -174.6 m (nominal P = 0.0183, HD combo vs. IAI); We …
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
Wykoff CC, Brown DM, Reed K, Berliner AJ, Gerstenblith AT, Breazna A, Abraham P, Fein JG, Chu KW, Clark WL, Leal S, Schmelter T, Hirshberg B, Yancopoulos GD, Vitti R; CANDELA Study Investigators. Wykoff CC, et al. Among authors: vitti r. JAMA Ophthalmol. 2023 Sep 1;141(9):834-842. doi: 10.1001/jamaophthalmol.2023.2421. JAMA Ophthalmol. 2023. PMID: 37535382
The proportion of eyes without fluid in the central subfield with 8-mg vs 2-mg aflibercept was 50.9% (n = 27) vs 34.0% (n = 18) (difference, 17.0 [95% CI, -1.6 to 35.5] percentage points; P = .08) at week 16 and 39.6% (n = 21) vs 28.3% (n = 15) (difference, 11.3 [95% CI, - …
The proportion of eyes without fluid in the central subfield with 8-mg vs 2-mg aflibercept was 50.9% (n = 27) vs 34.0% (n = 18) (difference, …
Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies.
Schmidt-Erfurth U, Kaiser PK, Korobelnik JF, Brown DM, Chong V, Nguyen QD, Ho AC, Ogura Y, Simader C, Jaffe GJ, Slakter JS, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Soo Y, Anderesi M, Sowade O, Zeitz O, Norenberg C, Sandbrink R, Heier JS. Schmidt-Erfurth U, et al. Among authors: vitti r. Ophthalmology. 2014 Jan;121(1):193-201. doi: 10.1016/j.ophtha.2013.08.011. Epub 2013 Sep 29. Ophthalmology. 2014. PMID: 24084500 Clinical Trial.

The number of injections during weeks 52 through 96 was lower in the 2q4 and 2q8 groups versus the Rq4 group (differences of -0.64 [95% CI, -0.89 to -0.40] and -0.55 [95% CI, -0.79 to -0.30]; P < 0.0001, post hoc analysis). Incidences of Antiplatelet Trialists' Collabor

The number of injections during weeks 52 through 96 was lower in the 2q4 and 2q8 groups versus the Rq4 group (differences of -0.64 [95% CI, …
An extended model of phosphorus metabolism in growing ruminants.
Dias RS, López S, Patiño RM, Silva TS, Silva Filho JC, Vitti DM, Peçanha MR, Kebreab E, France J. Dias RS, et al. Among authors: vitti dm. J Anim Sci. 2011 Dec;89(12):4151-62. doi: 10.2527/jas.2010-3669. Epub 2011 Jul 15. J Anim Sci. 2011. PMID: 21764835

Increased P intake positively affected total P (r = 0.97, P < 0.01) and endogenous P excretion in feces (r = 0.85, P < 0.01), P flow from plasma to saliva (r = 0.73, P < 0.01), from saliva to rumen (r = 0.73, P <

Increased P intake positively affected total P (r = 0.97, P < 0.01) and endogenous P excretion in feces (r =

Effects of phosphorus intake on phosphorus flow in growing pigs: application and comparison of two models.
Schulin-Zeuthen M, Lopes JB, Kebreab E, Vitti DM, Abdalla AL, Haddad MD, Crompton LA, France J. Schulin-Zeuthen M, et al. Among authors: vitti dm. J Theor Biol. 2005 Sep 21;236(2):115-25. doi: 10.1016/j.jtbi.2005.02.021. Epub 2005 Apr 18. J Theor Biol. 2005. PMID: 16005305
The Vitti model employs the rate:state formalism and describes phosphorus (P) flow between four pools representing P content in gut, blood, bone and soft tissue in growing goats. ...The pigs maintained their P homeostasis in blood by regulation of P ex …
The Vitti model employs the rate:state formalism and describes phosphorus (P) flow between four pools representing P content i …
A revised model for studying phosphorus and calcium kinetics in growing sheep.
Dias RS, Kebreab E, Vitti DM, Roque AP, Bueno IC, France J. Dias RS, et al. Among authors: vitti dm. J Anim Sci. 2006 Oct;84(10):2787-94. doi: 10.2527/jas.2006-082. J Anim Sci. 2006. PMID: 16971580
The objective of the study was to revise a model of P kinetics proposed by Vitti et al. (2000) and extend its use to study Ca flows in growing sheep. ...Phytate P digestibility was 47%, and P retention was negative (-1.4 g/d), suggesting that a feed character …
The objective of the study was to revise a model of P kinetics proposed by Vitti et al. (2000) and extend its use to study Ca flows i …
Thyroid autoimmunity, thyroglobulin autoantibodies, and thyroid cancer prognosis.
Viola N, Agate L, Caprio S, Lorusso L, Brancatella A, Ricci D, Sgrò D, Ugolini C, Piaggi P, Vitti P, Elisei R, Santini F, Latrofa F. Viola N, et al. Among authors: vitti p. Endocr Relat Cancer. 2023 Jun 2;30(7):e230042. doi: 10.1530/ERC-23-0042. Print 2023 Jul 1. Endocr Relat Cancer. 2023. PMID: 37043372
Time to remission was longer in the detectable than in the undetectable TgAb cohort (28.5 vs. 7.5 months (median); HR: 0.54, CI: 0.35-0.83, P = 0.005). When comparing PTC-LT to PTC patients, the difference was maintained in the detectable TgAb (29.3 vs 13.0 months; HR: 0.3 …
Time to remission was longer in the detectable than in the undetectable TgAb cohort (28.5 vs. 7.5 months (median); HR: 0.54, CI: 0.35-0.83, …
226 results